Enrollment is complete for the randomized part of ENHANCE, a Phase 3 trial testing a new dosing schedule for Briumvi in ...

Metis' MTS-004 was safe and eased symptoms of pseudobulbar affect in people with MS and other neurological disorders, trial data show.

A new study found that combining cognitive behavioral therapy (CBT) and a wakefulness medication significantly improved levels of fatigue in patients with multiple sclerosis (MS). The findings may ...

Medically reviewed by Gurdeep S. Sareen, PharmDMedically reviewed by Gurdeep S. Sareen, PharmD Even though multiple sclerosis (MS) cannot be cured, medications called disease-modifying therapies (DMTs ...

A suboptimal approach to medication management can lead to potentially harmful health outcomes. Most psychiatric drugs have side effects, and if a patient is not aware of them, they may seek ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment. Anaphylaxis symptoms can appear within an hour of injection and may lead to severe ...

People with multiple sclerosis appear to have higher rates of thyroid problems than the general population. The link isn’t clear, but shared pathways and MS medication side effects may play a role. MS ...

"AI-assisted medication management represents a powerful opportunity for critical and timely healthcare transformation to improve patient care, health system margins, and providers' experiences, all ...

Prof Nicholas Schwab and his colleagues found a biomarker which allows to tell in advance if therapy with glatirameracetate will be efficient in an individual MS patent. Treatment with interferon or ...